Literature DB >> 17708530

Tumor suppressor pRb2/p130 gene and its derived product Spa310 spacer domain as perspective candidates for cancer therapy.

Antonio Giordano1, Alessandra Rossi, Gaetano Romano, Luigi Bagella.   

Abstract

Tumor suppressor pRb2/p130 gene belongs to the retinoblastoma (Rb) gene family, which also includes pRb/p105 and pRb/p107. The members of the Rb gene family have attracted a great deal of interest because of their essential role in regulating cell cycle and, consequently, cell proliferation. This mini review discusses the potential therapeutic applications both of pRb2/p130 and its derived product Spa310 spacer domain in cancer treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17708530     DOI： 10.1002/jcp.21225

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN： 0021-9541            Impact factor:   6.384


  7 in total

1.  Proliferation and cell fate establishment during Arabidopsis male gametogenesis depends on the Retinoblastoma protein.

Authors:  Zhong Chen; Said Hafidh; Shi Hui Poh; David Twell; Frederic Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

2.  Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.

Authors:  Irene Marchesi; Luigi Bagella
Journal:  World J Clin Oncol       Date:  2016-04-10

Review 3.  Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?

Authors:  Alfredo Fucito; Chiara Lucchetti; Antonio Giordano; Gaetano Romano
Journal:  Int J Biochem Cell Biol       Date:  2007-10-23       Impact factor: 5.085

Review 4.  RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.

Authors:  Paola Indovina; Francesca Pentimalli; Nadia Casini; Immacolata Vocca; Antonio Giordano
Journal:  Oncotarget       Date:  2015-07-20

5.  Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2013-06-06

6.  Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2012-11-22

7.  Overexpression of E2F5/p130, but not E2F5 alone, can inhibit E2F-induced cell cycle entry in transgenic mice.

Authors:  Qin Chen; Dongcai Liang; Paul A Overbeek
Journal:  Mol Vis       Date:  2008-03-25       Impact factor: 2.367
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.